Syndax Pharmaceuticals has announced a significant funding milestone, successfully raising $350 million to bolster its innovative pipeline of first-in-class therapies aimed at addressing critical unmet medical needs in oncology. Based in Waltham, MA, Syndax is at the forefront of biopharmaceutical advancements, with a strong focus on developing transformative treatments for conditions like acute leukemia and chronic graft-versus-host disease (GVHD). The proceeds from this funding round will be strategically utilized to accelerate the development of their highly selective menin inhibitor, which shows promise for treating acute leukemia, as well as their groundbreaking monoclonal antibody that blocks the CSF-1 receptor and targets chronic GVHD. With several clinical trials already underway, Syndax is dedicated to unlocking the full potential of its robust pipeline and is committed to reimagining cancer care through innovative solutions. This investment not only reflects investor confidence in Syndax's vision and research capabilities but also underscores the urgency of advancing therapies that can make a meaningful difference in patients' lives. As Syndax continues to navigate the complexities of drug development, this financial boost positions the company to enhance its clinical initiatives and bring groundbreaking therapies to the market more swiftly, ultimately benefiting patients who are in desperate need of effective cancer treatments.
Syndax Pharmaceuticals Secures $350 Million in Funding to Revolutionize Cancer Care
Recently funded 路 $350.0MHealthcare
Get the full Syndax Pharmaceuticals company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
